- Page 3 and 4:
TABLE OF CONTENTSA. PERIODIC ACTIVI
- Page 5 and 6:
1 PUBLISHABLE EXECUTIVE SUMMARY EUR
- Page 7 and 8:
Dr. Davide Gabellini(28) Swiss Inst
- Page 9 and 10:
WP7 Molecular characterization of s
- Page 11 and 12:
To identify protein-protein interac
- Page 13 and 14:
expressed in a particular tissue. T
- Page 15 and 16:
Duchenne muscular dystrophy (DMD).
- Page 17 and 18:
WP21 Reachout to the broader RNA co
- Page 19 and 20:
4.1 TABLE OF MILESTONES JPA MONTH 2
- Page 21 and 22:
Numerous plasmids, constructs, extr
- Page 23 and 24:
collaboration between EURASNET and
- Page 25 and 26:
5.1 WORK PACKAGE REPORTSWork Packag
- Page 27 and 28:
• Ongoing regular addition of new
- Page 29 and 30:
Work Package 4 The Alternative Spli
- Page 31 and 32:
Work Package 6 In silico approaches
- Page 33 and 34:
alternative splicing.162 Compare sp
- Page 35 and 36:
33 Agreement on pre-mRNA substrates
- Page 37 and 38:
its numerous binding sites on both
- Page 39 and 40:
Work Package 8 Genome-wide Analyses
- Page 41 and 42:
173 Further development of data ana
- Page 43 and 44: Problems and explanations for delay
- Page 45 and 46: eveal that there is a dramatic chan
- Page 47 and 48: Work Package 10 Post-translational
- Page 49 and 50: mutational analysis that led to the
- Page 51 and 52: Isolation of an active step I splic
- Page 53 and 54: FBP11 and 21 with these sequences.
- Page 55 and 56: Similarly to what observed for SF2/
- Page 57 and 58: prp45-113 mutant, which is compatib
- Page 59 and 60: cell lines. In contrast in the pres
- Page 61 and 62: genes with roles in the development
- Page 63 and 64: Structural analyses of several RRMs
- Page 65: Work Package 17 Staff Exchange and
- Page 69 and 70: Barralle's lab, Krämer is acting a
- Page 71 and 72: alternative splicing) and higher ed
- Page 73 and 74: Student Symposium “Decision Makin
- Page 75 and 76: variation and suitability for use w
- Page 77 and 78: Following feedback from members we
- Page 79 and 80: Invited seminars: In addition to me
- Page 81 and 82: Publications 2008Author Title Publi
- Page 83 and 84: Author Title Publication EURASNET P
- Page 85 and 86: Author Title Publication EURASNET P
- Page 87 and 88: Author Title Publication EURASNET P
- Page 89 and 90: Author Title Publication EURASNET P
- Page 91 and 92: Author Title Publication EURASNET P
- Page 93: Minutes of the General Assembly dec
- Page 97 and 98: 258 Prepare Annual Report for 2008p
- Page 99 and 100: automated methods to update thepred
- Page 101 and 102: system, Bindereif incollaboration w
- Page 103 and 104: (e.g. A, B, or C) on thetranscripti
- Page 105 and 106: trans-acting factors of particulari
- Page 107 and 108: will further improve their U7-based
- Page 109 and 110: 7 UPDATED PLAN FOR USING AND DISSEM
- Page 111 and 112: Auweter S.D., Allain F.H.-T.Author
- Page 113 and 114: Author Title Publication EURASNET P
- Page 115 and 116: Author Title Publication EURASNET P
- Page 117 and 118: Author Title Publication EURASNET P
- Page 119 and 120: Lorković ZJ, Barta A.Author Title
- Page 121 and 122: 8 TABULAR OVERVIEW OF ALL RESOURCES
- Page 123 and 124: travel 0 300,06 774,06overhead 6.81
- Page 125 and 126: training 0 0equipment 0 0travel 0 2
- Page 127 and 128: consumables 14.093,34 1.617,49 8153
- Page 129 and 130: 10 JUSTIFICATION OF MAJOR COST ITEM
- Page 131 and 132: PersonnelScientific Network Manager
- Page 133 and 134: Participant 1C - Henning Urlauba) W
- Page 135 and 136: • WP21Lectured on RNA biology and
- Page 137 and 138: Bennewitz Elke 1.536,89Preller Rosa
- Page 139 and 140: Major cost items• ResearchPersonn
- Page 141 and 142: The second is hands on training for
- Page 143 and 144: Participant 6 - Gil Asta) Work perf
- Page 145 and 146:
these other hnRNP factors is of fun
- Page 147 and 148:
Participant 8 - Andrea Bartaa) Work
- Page 149 and 150:
Participant 9 - Jean Beggsa) Work p
- Page 151 and 152:
Participant 10A - Giuseppe Biamonti
- Page 153 and 154:
Participant 10B - Glauco Tocchini-V
- Page 155 and 156:
Participant 11 - Albrecht Bindereif
- Page 157 and 158:
Presented EURASNET-related material
- Page 159 and 160:
) Major cost items with justificati
- Page 161 and 162:
effects of HeLa cell’s growth con
- Page 163 and 164:
ConsumablesOligonucleotidesChemical
- Page 165 and 166:
c) Main activities planned for the
- Page 167 and 168:
) Major cost items with justificati
- Page 169 and 170:
Participant 16 - Maria Carmo-Fonsec
- Page 171 and 172:
Participant 17 - Ian C. Eperona) Wo
- Page 173 and 174:
Participant 18 - Artur Jarmolowskia
- Page 175 and 176:
Participant 19 - Jørgen Kjemsa) Wo
- Page 177 and 178:
Participant 20 - Alberto Kornblihtt
- Page 179 and 180:
• ResearchPersonnelIvona Bagdiul
- Page 181 and 182:
The stable cell lines have been tes
- Page 183 and 184:
Participant 24 - Hermona Soreqa) Wo
- Page 185 and 186:
Participant 25 - James SteveninWP 7
- Page 187 and 188:
Participant 27 - Davide Gabellinia)
- Page 189 and 190:
Participant 28 - Mihaela Zavolana)
- Page 191 and 192:
Participant 30 - Janusz Bujnickia)
- Page 193 and 194:
Participant 31 - Eduardo Eyrasa) Wo
- Page 195 and 196:
Participant 32 - Diana Barallea) Wo
- Page 197 and 198:
MPG1aMPG1bMPG1cCRGUERLNUUEMBL5aEMBL
- Page 199 and 200:
Type of Instrument NoE Project Titl
- Page 201 and 202:
Direct eligible costs 39.626,75 0,0
- Page 203 and 204:
Direct eligible costs 0,00 0,00 0,0
- Page 205 and 206:
Report on the Distribution of the C
- Page 207 and 208:
14 SUMMARY EXPLANATION OF THE IMPAC
- Page 209 and 210:
The website is an important tool fo
- Page 211 and 212:
By February 2009 ASTD and Integr8 w
- Page 213 and 214:
will prove necessary to focus the s
- Page 215 and 216:
Work Package 10: Post-translational
- Page 217 and 218:
splicing (c-fos) increases when elo
- Page 219 and 220:
TABLE: Relationship of transcriptio
- Page 221 and 222:
HIV-1 and other retroviruses inhibi
- Page 223 and 224:
experiments. We will also attempt t
- Page 225 and 226:
[This page deliberately left empty.
- Page 227 and 228:
18. CAREER DEVELOPMENT (Kjems)caree
- Page 229 and 230:
Interactions among EURASNET partici
- Page 231 and 232:
15.5 DELIVERABLES LIST (MONTHS 37-5
- Page 233 and 234:
163 The Eyras group incollaboration
- Page 235 and 236:
202 Srebrow will investigate therol
- Page 237 and 238:
224 Schümperli's group willfurther
- Page 239 and 240:
267 GROUP 16 (CARMO- 12 F. Baralle
- Page 241 and 242:
288 Groups 12a (C Branlant) willcon
- Page 243 and 244:
306 Establishing interaction mapsam
- Page 245 and 246:
320 Tazi has identified theDrosophi
- Page 247 and 248:
330 GROUP 11 (BINDEREIF)will contin
- Page 249 and 250:
338 Role of the U1 snRNP in“rever
- Page 251 and 252:
352 Arrangement of a 1-daycareer de
- Page 253 and 254:
15.6 JOINT PROGRAM OF ACTIVITIES (M
- Page 255 and 256:
4. The Alternative Splicing and Tra
- Page 257 and 258:
6. In silico approaches to alternat
- Page 259 and 260:
287 Group 7 (F Baralle) will contin
- Page 261 and 262:
Deliverables176, 180, 184, 185 all
- Page 263 and 264:
10. Post-translational Modification
- Page 265 and 266:
11. Function of Splicing Factor Iso
- Page 267 and 268:
properties of the human TDP-43 prot
- Page 269 and 270:
339 Establishment of “model genes
- Page 271 and 272:
223 Development of clinically usefu
- Page 273 and 274:
16. Conferences and meetingsWorkpac
- Page 275 and 276:
17. Staff Exchange and TrainingWork
- Page 277 and 278:
19. Public Understanding of RNA Bio
- Page 279 and 280:
Deliverables249 Screen at least 10,
- Page 281 and 282:
22. ManagementWorkpackage descripti
- Page 283 and 284:
15.8 PMs FOR THE 4th 18 MONTH PERIO
- Page 285 and 286:
15.9 Efforts for the full duration
- Page 287 and 288:
16 Project management level descrip
- Page 289 and 290:
630,000 € 180,000 € 210,000 €
- Page 291 and 292:
290Fig. 7 Budget
- Page 293 and 294:
Joint Programme of ActivitiesINTEGR
- Page 295 and 296:
The Meeting and conference programm